StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a report released on Friday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Stock Up 2.9 %
Evoke Pharma stock opened at $5.32 on Friday. The stock has a market cap of $45.74 million, a P/E ratio of -2.91 and a beta of 0.39. Evoke Pharma has a twelve month low of $3.54 and a twelve month high of $17.88. The company’s 50-day moving average price is $4.80 and its two-hundred day moving average price is $5.67.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.21). Evoke Pharma had a negative net margin of 86.74% and a negative return on equity of 964.25%. The company had revenue of $2.55 million during the quarter.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Further Reading
- Five stocks we like better than Evoke Pharma
- P/E Ratio Calculation: How to Assess Stocks
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- What to Know About Investing in Penny Stocks
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- How to Use High Beta Stocks to Maximize Your Investing Profits
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.